すべての画像(1)

主要文書

EHU125271

MISSION^® esiRNA

Name: MISSION<SUP>®</SUP> esiRNA
Brand: SIGMA

targeting human PLAUR

ログイン組織・契約価格を表示する

すべての画像(1)

About This Item

UNSPSCコード:

41105324

NACRES:

NA.51

おすすめの製品

Slide 1 of 10

1 of 10

Roche

SITRAN-RO

X-tremeGENE^™ siRNAトランスフェクション試薬

Sigma-Aldrich

EHU132661

MISSION^® esiRNA

Sigma-Aldrich

SIC001

MISSION^® siRNA Universal Negative Control #1

SIRNA

MISSION^® siRNA Product Offerings

Roche

XTG360-RO

X-tremeGENE^™ 360トランスフェクション試薬

Sigma-Aldrich

SHC016

MISSION^® pLKO.1-puro 非標的shRNAコントロールプラスミドDNA

SHRNA

MISSION^® shRNA Product Offerings

Sigma-Aldrich

SHC216

MISSION^® TRC2 pLKO.5-puro非標的shRNAコントロールプラスミドDNA

Roche

XTG9-RO

X-tremeGENE^™ 9 DNAトランスフェクション試薬

Roche

XTGHP-RO

X-tremeGENE^™ HP DNA トランスフェクション試薬

詳細

品質水準

100

製品種目

MISSION^®

フォーム

lyophilized powder

esiRNA cDNA標的配列

GACCCTGAGCTATCGGACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAGGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGTGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCTGAAGAACAGTGCCTGGATG

Ensembl |ヒトアクセッション番号

ENSG00000011422

NCBIアクセッション番号

NM_001005376

輸送温度

ambient

保管温度

−20°C

遺伝子情報

human ... PLAUR(5329) , PLAUR(5329)

詳細

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

法的情報

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

適切な製品が見つかりませんか。

製品選択ツール.をお試しください

保管分類コード

10 - Combustible liquids

引火点(°F)

Not applicable

引火点(℃)

Not applicable

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

ZPT

WNS

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

COAを検索

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Urokinase-type plasminogen activator receptor inhibits apoptosis in triple-negative breast cancer through miR-17/20a suppression of death receptors 4 and 5.

Xin Li et al.

Oncotarget, 8(51), 88645-88657 (2017-11-29)

Dissection and understanding of the molecular pathways driving triple-negative breast cancer (TNBC) are urgently needed to develop efficient tailored therapies. Aside from cell invasion and metastasis, the urokinase-type plasminogen activator receptor (uPAR) has been linked to apoptosis resistance in breast

Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.

K D Rysenkova et al.

Cellular signalling, 75, 109741-109741 (2020-08-22)

Urokinase-type plasminogen activator uPA and its receptor (uPAR) are the central players in extracellular matrix proteolysis, which facilitates cancer invasion and metastasis. EGFR is one of the important components of uPAR interactome. uPAR/EGFR interaction controls signaling pathways that regulate cell

uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells.

Anna Laurenzana et al.

International journal of cancer, 141(6), 1190-1200 (2017-06-04)

In this manuscript, we show the involvement of the uPA/uPAR system in the regulation of aerobic glycolysis of melanoma cells. uPAR over-expression in human melanoma cells controls an invasive and glycolytic phenotype in normoxic conditions. uPAR down-regulation by siRNA or

PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis.

M Unseld et al.

Thrombosis and haemostasis, 114(2), 379-389 (2015-05-01)

The tumour suppressor phosphatase and tensin homologue (PTEN), mutated or lost in many human cancers, is a major regulator of angiogenesis. However, the cellular mechanism of PTEN regulation in endothelial cells so far remains elusive. Here, we characterise the urokinase

Silencing of uPAR via RNA interference inhibits invasion and migration of oral tongue squamous cell carcinoma.

Xuexiang Gao et al.

Oncology letters, 16(3), 3983-3991 (2018-08-22)

Overexpression of urokinase-type plasminogen activator receptor (uPAR) has been implicated in promoting tumor invasion in various cancer types, including oral tongue squamous cell carcinoma (OTSCC); therefore, the effect of suppressing uPAR expression on the invasive and metastatic potential of OTSCC

主要文書

MISSION^® esiRNA